



## Connect Biopharma to Participate at the SVB Leerink 11th Annual Global Healthcare Conference

February 9, 2022

SAN DIEGO and TAICANG, China, Feb. 09, 2022 (GLOBE NEWSWIRE) -- [Connect Biopharma](#) Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Dr. Zheng Wei, Co-Founder & CEO, will participate in a fireside chat at the SVB Leerink 11<sup>th</sup> Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 4:20 pm ET.

A webcast of this fireside chat will be available on the Company's Investor Relations page accessible here: <https://investors.connectbiopharm.com/>. A replay will be available on the Company's website following the event.

### About Connect Biopharma Holdings Limited

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from our T cell-driven research.

Our lead product candidate, CBP-201 — an antibody designed to target interleukin-4 receptor alpha (IL-4R $\alpha$ ) — has been in clinical trials for the treatment of AD, asthma, and CRSwNP. Our second lead product candidate, CBP-307 — a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1) — has been in clinical trials for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). Furthermore, we have started the clinical development of an additional product candidate, CBP-174 — a peripherally acting antagonist of histamine receptor 3 — for the treatment of pruritus associated with AD.

With clinical development activities in the United States, China, Europe, and Australia, and operations in those geographies as well as Hong Kong, Connect Biopharma is building a rich global pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. For additional information about Connect Biopharma, please visit our website at [www.connectbiopharm.com](http://www.connectbiopharm.com).

### IR/PR Contacts:

Lazar FINN Partners

David Carey (IR)

T: +1-(212) 867-1768

[david.carey@finnpartners.com](mailto:david.carey@finnpartners.com)

Erich Sandoval (Media)

T: +1-(917)-497-2867

[erich.sandoval@finnpartners.com](mailto:erich.sandoval@finnpartners.com)

### Corporate Contacts:

[info@connectpharm.com](mailto:info@connectpharm.com)